These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 3929266

  • 1. A long term follow-up of patients with advanced prostatic cancer treated with buserelin.
    Waxman JH, Hendry WF, Whitfield HN, Oliver RT.
    Prog Clin Biol Res; 1985; 185A():271-7. PubMed ID: 3929266
    [Abstract] [Full Text] [Related]

  • 2. Treatment of advanced prostatic cancer with buserelin, an analogue of gonadotrophin releasing hormone.
    Waxman JH, Wass JA, Hendry WF, Whitfield HN, Bary P, Besser GM, Malpas JS, Oliver RT.
    Br J Urol; 1983 Dec; 55(6):737-42. PubMed ID: 6418264
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of buserelin in advanced prostate cancer and comparison with historical controls.
    Soloway MS.
    Am J Clin Oncol; 1988 Dec; 11 Suppl 1():S29-32. PubMed ID: 3133944
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A review of the Hammersmith Hospital, St. Bartholomew's Hospital, and Institute of Urology studies of buserelin in advanced prostatic cancer.
    Waxman J.
    Am J Clin Oncol; 1988 Dec; 11 Suppl 1():S16-8. PubMed ID: 3133943
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Treatment of locally advanced prostatic carcinoma with LHRH analogues: cytological, DNA-cytophotometrical, and clinical results.
    Borgmann V, al-Abadi H, Nagel R.
    Am J Clin Oncol; 1988 Dec; 11 Suppl 1():S19-28. PubMed ID: 2968759
    [Abstract] [Full Text] [Related]

  • 8. [Treatment of prostatic cancer with intranasal administration of LHRH analog, Buserelin (Hoe 766) study of the optimum dosage of intranasal application].
    Niijima T, Kishimoto T, Shimazaki J, Yoshida O, Isurugi K.
    Hinyokika Kiyo; 1988 Jul; 34(7):1309-19. PubMed ID: 3140622
    [Abstract] [Full Text] [Related]

  • 9. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide).
    Kuhn JM, Billebaud T, Navratil H, Moulonguet A, Fiet J, Grise P, Louis JF, Costa P, Husson JM, Dahan R.
    N Engl J Med; 1989 Aug 17; 321(7):413-8. PubMed ID: 2503723
    [Abstract] [Full Text] [Related]

  • 10. Endocrine and clinical evaluation of 107 patients with advanced prostatic carcinoma under long-term pernasal buserelin or intramuscular decapeptyl depot treatment.
    Jacobi GH, Wenderoth UK, Ehrenthal W, von Wallenberg H, Spindler HW, Hohenfellner R.
    Am J Clin Oncol; 1988 Aug 17; 11 Suppl 1():S36-43. PubMed ID: 2968761
    [Abstract] [Full Text] [Related]

  • 11. Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer.
    Waxman JH, Wass JA, Hendry WF, Whitfield HN, Besser GM, Malpas JS, Oliver RT.
    Br Med J (Clin Res Ed); 1983 Apr 23; 286(6374):1309-12. PubMed ID: 6404441
    [Abstract] [Full Text] [Related]

  • 12. [Treatment of advanced cancer of the prostate with an analog of LHRH, buserelin].
    Wenderoth UK, Jacobi GH.
    Ann Urol (Paris); 1986 Apr 23; 20(2):95-7. PubMed ID: 3087269
    [Abstract] [Full Text] [Related]

  • 13. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
    Lukkarinen O, Kontturi M.
    Scand J Urol Nephrol Suppl; 1988 Apr 23; 110():109-12. PubMed ID: 2973121
    [Abstract] [Full Text] [Related]

  • 14. Use of gonadotropin-releasing hormone analogue in advanced prostatic cancer: 3 years clinical experience.
    Matzkin H, Greenstein A, Kaver I, Braf Z.
    Isr J Med Sci; 1989 Jul 23; 25(7):388-92. PubMed ID: 2474522
    [Abstract] [Full Text] [Related]

  • 15. Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate a 12-month follow-up study.
    Pettersson B, Varenhorst E, Petas A, Sandow J.
    Eur Urol; 2006 Sep 23; 50(3):483-9. PubMed ID: 16626856
    [Abstract] [Full Text] [Related]

  • 16. Long-term endocrine profiles of prostatic carcinoma patients under pernasal as well as intramuscular Gn-RH analogue treatment.
    Wenderoth UK, Jacobi GH.
    Prog Clin Biol Res; 1985 Sep 23; 185A():297-305. PubMed ID: 3162176
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Metastatic prostate cancer under long term pernasal buserelin or intramuscular decapeptyl depot treatment.
    Wenderoth UK, Spindler HW, Ehrenthal W, von Wallenberg H, Happ J, Jacobi GH.
    Prog Clin Biol Res; 1987 Sep 23; 243A():207-20. PubMed ID: 2958851
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.